plerixafor has been researched along with Acute Kidney Failure in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Ren, R; Ren, X; Shang, J; Wang, Y | 1 |
| Fricker, SP; Gershenovich, M; Ivanova, Y; Ledbetter, S; MacFarland, RT; Zuk, A | 1 |
| Hu, X; Xu, Y; Zeng, S; Zhang, Q; Zhang, Z | 1 |
1 review(s) available for plerixafor and Acute Kidney Failure
| Article | Year |
|---|---|
Stem Cell Mobilizers: Novel Therapeutics for Acute Kidney Injury.
Topics: Acute Kidney Injury; Animals; Benzylamines; Chemokine CXCL12; Cyclams; Disease Models, Animal; Gene Expression Regulation; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Kidney; Matrix Metalloproteinase 9; Mice; Receptors, CXCR4; Signal Transduction | 2017 |
2 other study(ies) available for plerixafor and Acute Kidney Failure
| Article | Year |
|---|---|
The combination of G-CSF and AMD3100 mobilizes bone marrow-derived stem cells to protect against cisplatin-induced acute kidney injury in mice.
Topics: Acute Kidney Injury; Animals; Benzylamines; Bone Marrow; Cisplatin; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Mice; Mice, Inbred C57BL; Stem Cells | 2021 |
CXCRâ‚„antagonism as a therapeutic approach to prevent acute kidney injury.
Topics: Acute Kidney Injury; Animals; Benzylamines; Chemokine CXCL12; Cyclams; Flow Cytometry; Hematopoietic Stem Cells; Heterocyclic Compounds; Kidney Function Tests; Leukocytes; Male; Pyridines; Rats, Sprague-Dawley; Rats, Wistar; Receptors, CXCR4; Reperfusion Injury | 2014 |